Tag Archive | "Nycomed"

Eurand, Nycomed reach marketing deal for Zenpep

Tags: ,


Eurand N.V. and Nycomed have announced that Eurand has entered into an exclusive commercialisation, license and supply agreement with Nycomed for Russia and the Commonwealth of Independent States (CIS), as well as Georgia and Mongolia. Financial terms were not disclosed. Read the full story

BTG signs $16.6m deal to sell Nycomed’s antivenom drugs

Tags: ,


BTG plc has announced that it has signed an agreement with Nycomed US Inc. concerning the accelerated transition to BTG on 1 October 2010 of marketing rights to CroFab™ (Crotalidae Polyvalent Immune Fab (Ovine)), an antivenom, and DigiFab™ (Digoxin Immune Fab (Ovine)), for treating patients with life-threatening digoxin toxicity or overdose. Read the full story

15 Years Old, Going Strong, And Continuously Innovating

Tags: , , ,


On the 20th of June 1995 the first euroPLX Meeting was held in Frankfurt, Germany. At that time it was called “European Pharma Licensing Meeting”, a name which was later changed to European Pharma License Exchange, or euroPLX, for short. Read the full story

Nycomed wins EU approval for COPD therapy

Tags: ,


Despite being rebuffed by the FDA and its drug experts, Switzerland's Nycomed has won EU approval for Daxas, its new therapy to treat chronic obstructive pulmonary disorder. T Read the full story

Quintiles bolsters market access capabilities by taking on Nycomed’s Healthcare Solutions team

Tags: ,


Quintiles and Nycomed today announced an agreement under which the privately-held Swiss pharmaceutical company has transferred a UK-based Healthcare Solutions Team to Quintiles. Read the full story

Merck & Co to help sell Nycomed lung drug Daxas in EU, Canada

Tags: , ,


Nycomed will receive an undisclosed upfront fee from Merck and is eligible for certain payments based on defined regulatory and commercialization milestones for Daxas. Read the full story

Small molecule strategies continue to produce new COPD therapy targets

Tags: , , , ,


The development of small molecule therapies continues at pace with news that Roche is the latest company to license the Galapagos discovery platform to develop new treatments for COPD. Read the full story

DURECT and Nycomed amend POSIDUR license agreement to separate funding and control of US and EU clinical programs and to expand territory

Tags: ,


The amendment provides DURECT with final decision-making authority over clinical trials intended for the U.S. registration of POSIDUR and Nycomed with decision-making authority over clinical trials for the E.U. and other countries licensed to it. Read the full story

Abbott joins bidding for Solvay drug unit

Tags: , , ,


Abbott Laboratories has emerged as a strong competitor to purchase the pharmaceutical unit of Belgian conglomerate Solvay SA, setting up a potential showdown with rival bidder Nycomed for a deal that could be valued at €4 billion to €5 billion ($5.9 billion to $7.4 billion).

Nycomed makes 4-4.5 million Euro Solvay bid

Tags: ,


If successful a tie-up would create a group with about 6 billion euros in annual sales and would be the first takeover to be funded significantly by European "junk" bonds since the financial crisis began.

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cabannerad300x150new4gif
e80banner300x150animgif
a1banner300x150animgif